Cell populations which co-express CD49c and CD90

• US 10,351,826 B2
• Filed: 05/02/2007
• Issued: 07/16/2019
• Est. Priority Date: 09/21/2001
• Status: Active Grant

• Current Assignee: Garnet Biotherapeutics Incorporated
• Original Assignee: Garnet Biotherapeutics Incorporated
• Inventors: Ho, Tony W., Kopen, Gene C., Righter, William F., Rutkowski, J. Lynn, Wagner, Joseph
• Primary Examiner(s): Kim, Taeyoon
• Application Number:
  US11/797,322
• Publication Number:
  US 20070264232A1
• Time in Patent Office: 4,458 Days
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 21/04 for myasthenia gravis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/00 Drugs for disorders of the endocrine system
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/04 Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12N 2500/02 Atmosphere, e.g. low oxygen conditions
• CPC Class Codes: C12N 2500/32 Amino acids
• CPC Class Codes: C12N 2506/1353 from bone marrow mesenchymal stem cells (BM-MSC)
• CPC Class Codes: C12N 5/0623 Stem cells
• CPC Class Codes: C12N 5/0663 Bone marrow mesenchymal stem cells (BM-MSC)
• CPC Class Codes: C12N 5/0669 Bone marrow stromal cells; Whole bone marrow isolated stem cells from bone marrow C12N5/0647, C12N5/0663

Abstract

Substantially homogenous cells populations which co-express CD49c, CD90 and telomerase are made. In one embodiment, humans suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition are treated with the substantially homogenous cells populations which co-express CD49c, CD90 and telomerase. In another embodiment, committed progenitor cells are made are made by selecting from a cultured source of a cell population which co-express CD49c and CD90 and modifying the cell population. The committed progenitor cells can be employed to treat a human suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition and formulate pharmaceutical compositions.

Claims

1. An isolated cell population of human bone marrow-derived cells, wherein said cell population is obtained by culturing bone marrow cells in vitro at cell seeding densities of about 30 cells/cm² under about 5% oxygen conditions for more than 30 population doublings, wherein said cell population continues to maintain a population doubling time of about 30 hours per doubling and wherein greater than 91% of the cells in said cell population continue to co-express cell surface markers CD49c and CD90, and wherein said cell population does not express cell surface markers CD34 or CD45, and wherein said cell population expresses telomerase at a relative expression of between about 1 transcript of telomerase per 10⁶ transcripts of an 18s rRNA and about 10 transcripts of telomerase per 10⁶ transcripts of an 18s rRNA, and further wherein the isolated cell population expresses brain derived neurotrophic factor.

2. The isolated cell population of human bone marrow-derived cells of claim 1, wherein said cell population expresses telomerase at a relative expression of about 1 transcript of telomerase per 10⁶ transcripts of an 18s rRNA.

3. The isolated cell population of human bone marrow-derived cells of claim 1, wherein said cell population expresses telomerase at a relative expression of about 5 transcripts of telomerase per 10⁶ transcripts of an 18s rRNA.

4. The isolated cell population of human bone marrow-derived cells of claim 1, wherein said cell population expresses telomerase at a relative expression of about 10 transcripts of telomerase per 10⁶ transcripts of an 18s rRNA.